A Dose-finding Study of OPC-6535 in Patients With Active Crohn's Disease
Status:
Terminated
Trial end date:
2007-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study to examine the safety and efficacy of OPC-6535 and determine its
optimal dose by once-daily oral administration at 0, 25, or 50 mg for 8 weeks in combination
with a fixed oral dose of 5-aminosalicylic acid (5-ASA) or in combination with a fixed oral
dose of 5-ASA and enteral nutrition in patients with active Crohn's disease.